Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
or

Aerovate Therapeutics Inc (AVTE)

Aerovate Therapeutics Inc (AVTE)
2.74 x 2 2.75 x 2
Post-market by (Cboe BZX)
2.74 -0.02 (-0.72%) 04/23/25 [NASDAQ]
2.74 x 2 2.75 x 2
Post-market 2.75 +0.01 (+0.36%) 18:21 ET
Quote Overview for Wed, Apr 23rd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
2.72
Day High
2.82
Open 2.79
Previous Close 2.76 2.76
Volume 504,094 504,094
Avg Vol 302,845 302,845
Stochastic %K 76.13% 76.13%
Weighted Alpha +48.32 +48.32
5-Day Change +0.05 (+1.86%) +0.05 (+1.86%)
52-Week Range 1.25 - 25.28 1.25 - 25.28
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 79,999
  • Shares Outstanding, K 28,985
  • Annual Sales, $ 0 K
  • Annual Income, $ -69,630 K
  • EBIT $ -75 M
  • EBITDA $ -77 M
  • 60-Month Beta 0.95
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.05

Options Overview Details

View History
  • Implied Volatility 79.60% ( +7.51%)
  • Historical Volatility 19.70%
  • IV Percentile 25%
  • IV Rank 5.23%
  • IV High 1,436.07% on 02/12/25
  • IV Low 4.69% on 02/18/25
  • Put/Call Vol Ratio 6.00
  • Today's Volume 217
  • Volume Avg (30-Day) 120
  • Put/Call OI Ratio 3.69
  • Today's Open Interest 4,018
  • Open Int (30-Day) 3,918

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.30
  • Number of Estimates 2
  • High Estimate -0.18
  • Low Estimate -0.41
  • Prior Year -0.83
  • Growth Rate Est. (year over year) +63.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.45 +11.84%
on 04/04/25
Period Open: 2.52
2.86 -4.20%
on 04/22/25
+0.22 (+8.73%)
since 03/21/25
3-Month
2.24 +22.32%
on 03/18/25
Period Open: 2.56
2.86 -4.20%
on 04/22/25
+0.18 (+7.03%)
since 01/23/25
52-Week
1.25 +119.20%
on 06/20/24
Period Open: 23.22
25.28 -89.16%
on 06/14/24
-20.48 (-88.20%)
since 04/23/24

Most Recent Stories

More News
Small Cap News Movers: Your Daily Digest of Stocks Making Moves on Market News

The broader market experienced mixed performance to start the week, with major indices showing volatility but ultimately closing higher. On Monday, Dow Jones Industrial Average (DJI) gained 0.78%. The...

JNVR : 55.06 (+22.74%)
SKYE : 1.7300 (+14.57%)
AVTE : 2.74 (-0.72%)
RXRX : 5.58 (-0.89%)
CERT : 14.25 (-1.38%)
^SOLUSD : 151.1325 (+0.10%)
UAMY : 3.44 (+5.52%)
Small Cap News Movers: Your Daily Digest of Stocks Making Moves on Market News

SKYE : 1.7300 (+14.57%)
JNVR : 55.06 (+22.74%)
AVTE : 2.74 (-0.72%)
RXRX : 5.58 (-0.89%)
CERT : 14.25 (-1.38%)
UAMY : 3.44 (+5.52%)
Small Cap News Movers: Your Daily Digest of Stocks Making Moves on Market News

The broader market experienced mixed performance on Monday, with major indices showing volatility but ultimately closing higher. The Dow Jones Industrial Average gained 0.78%. The S&P 500 rose 0.79%, and...

JNVR : 55.06 (+22.74%)
SKYE : 1.7300 (+14.57%)
AVTE : 2.74 (-0.72%)
RXRX : 5.58 (-0.89%)
CERT : 14.25 (-1.38%)
UAMY : 3.44 (+5.52%)
Aerovate Therapeutics Stock Bucks Broader Market Sell-Off Over Dividend Announcement: Stock Rises But Retail’s Unmoved

The company said that the official declaration of the cash dividend will be subject to the approval of Aerovate board of directors and is expected to be announced later this month.

AVTE : 2.74 (-0.72%)
VTI : 263.44 (+1.70%)
IWM : 190.25 (+1.48%)
Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH)

AV-101 is being developed to address cellular hyperproliferation and resistance to apoptosis in the pulmonary vasculature, which are key features of the...

AVTE : 2.74 (-0.72%)
Aerovate Therapeutics Announces First Quarter 2022 Financial Results

WALTHAM, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on...

AVTE : 2.74 (-0.72%)
Aerovate Therapeutics Announces Full-Year 2021 Financial Results

Initiated IMPAHCT, a global Phase 2b/Phase 3 trial of AV-101 for pulmonary arterial hypertension (PAH) in December 2021Received FDA guidance in April 2021...

AVTE : 2.74 (-0.72%)
Aerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial Hypertension

WALTHAM, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on...

AVTE : 2.74 (-0.72%)
Aerovate Therapeutics Announces Third Quarter 2021 Financial Results

WALTHAM, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on...

AVTE : 2.74 (-0.72%)
Aerovate Therapeutics Announces Its Addition to the Russell 2000® Index

WALTHAM, Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc.  (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the...

AVTE : 2.74 (-0.72%)

Business Summary

Aerovate Therapeutics Inc. is a clinical stage biopharmaceutical company. It focused on developing drugs for cardiopulmonary disease. The company's product pipeline consist AV-101. Aerovate Therapeutics Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 2.92
2nd Resistance Point 2.87
1st Resistance Point 2.81
Last Price 2.74
1st Support Level 2.70
2nd Support Level 2.65
3rd Support Level 2.59

See More

52-Week High 25.28
Fibonacci 61.8% 16.10
Fibonacci 50% 13.27
Fibonacci 38.2% 10.43
Last Price 2.74
52-Week Low 1.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective